SABCS 2024 - Dr. Ayoub’s Expert Insights on DESTINY-Breast12

Dr. Jean-Pierre Ayoub shares insights on the DESTINY-Breast12 trial, highlighting the reassuring effects of T-DXd on quality of life and neurological function in HER2+ metastatic breast cancer patients, with or without brain metastases.